EMA Withdrawn: Osseor (strontium ranelate) — Les Laboratoires Servier

View source ↗

Summary

The EMA has withdrawn Osseor (strontium ranelate) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Osseor (strontium ranelate)

Snippet

Status: Withdrawn. Therapeutic area: Osteoporosis, Postmenopausal. MAH: Les Laboratoires Servier. Decision date: 22/05/2018